Compositions for coating microcapsules and other surfaces

• US 6,231,892 B1
• Filed: 11/13/1997
• Issued: 05/15/2001
• Est. Priority Date: 10/15/1990
• Status: Expired due to Fees

• Current Assignee: Board of Regents of the University of Texas System (University of Texas System)
• Original Assignee: Board of Regents of the University of Texas System (University of Texas System)
• Inventors: Sawhney, Amarpreet S., Hubbell, Jeffrey A.
• Primary Examiner(s): Spear, James M.
• Application Number:
  US08/969,910
• Time in Patent Office: 1,279 Days
• Field of Search: 424/490, 424/497, 424/423, 424/491, 424/493, 424/78.08, 424/78.17
• US Class Current: 424/491
• CPC Class Codes: A61K 47/60 the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• CPC Class Codes: A61K 47/645 Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
• CPC Class Codes: A61K 47/6925 the form being a microcapsule, nanocapsule, microbubble or nanobubble
• CPC Class Codes: A61K 9/5031 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
• CPC Class Codes: A61K 9/5073 having two or more different coatings optionally including drug-containing subcoatings

Abstract

Biocompatible microcapsules useful for transplanting foreign material into an animal body, and the method of their production, are described, wherein the microcapsules contain an outermost layer of water soluble non-ionic polymers such as PEO to create resistance to cell adhesion on the surface of the microcapsules.

Claims

1. A pharmaceutically acceptable composition which reduces cellular adhesion to a surface to which the composition is applied comprising:

a water soluble block copolymer comprising at least one polycationic polymer block grafted to at least one hydrophilic, water soluble, non-ionic polymer block,

in combination with a polyanionic polymer which binds to the block copolymer such that the outerlayer of the composition is a hydrophilic and uncharged polymer layer.

2. The composition of claim 1, wherein the block copolymer is capable of adhering to a surface by ionic bonding.

3. The composition of claim 1, wherein the polycationic polymer is selected from the group consisting of a polyamide, a polyimine, and a polyamine, with a weight average molecular weight of between 10,000 and 75,000 daltons.

4. The composition of claim 3, wherein the polycationic polymer is selected from the group consisting of polylysine, polyornithine, polyethyleneimine, polyallylamine, and copolymers and mixtures thereof.

7. The composition of claim 1 wherein the block copolymer comprises a plurality of water soluble, non-ionic polymer blocks grafted to a polycationic polymer block, and the non-ionic water soluble polymer is selected from the group consisting of poly(ethylene oxide), poly(vinyl pyrrolidone), poly(ethyl oxazoline), poly(vinyl alcohol), polysaccharides, and mixtures thereof.

8. The composition of claim 1, wherein the composition is provided in a pharmaceutically acceptable aqueous solution.

9. The composition of claim 1, wherein treatment of a surface with the composition results in an improvement in biocompatibility of the surface which is detectable by a property selected from the group consisting of:

a) a decrease of adherence to the surface of cells from an animal; and

b) a decrease of the immune response of an animal to the surface.

10. The composition of claim 7 wherein the block copolymer comprises a positive charge.

5. A pharmaceutically acceptable composition comprising:

a water soluble block copolymer comprising at least one polycationic polymer block grafted to at least one hydrophilic, water soluble, non-ionic polymer block having a weight average molecular weight between 2000 and 100,000 daltons,

in combination with a polyanionic polymer which binds to the block copolymer to form a hydrophilic, uncharged polymer layer.

6. The composition of claim 5, wherein the non-ionic water soluble polymer is poly(ethylene oxide) with a weight average molecular weight of 2000 to 50,000 daltons.

11. A composition suitable for treating a surface to improve its biocompatibility and resistance to cellular overgrowth, comprising:

an aqueous solution of a pharmaceutically acceptable water-soluble block copolymers, the block copolymer comprising a water-soluble non-ionic polymer and a polycationic polymer, in combination with a polyanionic polymer which binds to the block copolymer to form a hydrophilic, uncharted polymer layer effective to shield a surface from cellular adhesion.

12. The composition of claim 11, wherein the block copolymer is capable of ionically crosslinking to the surface.

13. The composition of claim 11, wherein the polycationic polymer is selected from the group consisting of polypeptides, polyimines, and polyallylamines, and wherein the weight average molecular weight of the polycationic polymer is between 10,000 and 75,000 daltons.

14. The composition of claim 13, where the polycationic polymer is selected from the group consisting of polylysine, polyornithine, polyethyleneimine, polyallylamine, mixed copolymers thereof, and mixtures thereof.

15. The composition of claim 11, wherein the non-ionic water-soluble polymer is selected from the group consisting of poly(ethylene oxide), poly(vinylpyrrolidone), poly(ethyloxazoline), poly(vinyl alcohol), and polysaccharides, and wherein the weight average molecular weight is between 2000 and 50,000 daltons.

16. The composition of claim 11, wherein the block copolymer comprises a polycationic polymer backbone having non-ionic water soluble polymeric sidechains bound thereto.

17. A method for improving the biocompatibility of a microcapsule comprising a polyanionic polymer on its surface, comprising adding a composition comprising a pharmaceutically acceptable water-soluble block copolymer to an aqueous solution containing the microcapsule,

wherein the copolymer comprises a water-soluble non-ionic polymer grafted to a polycationic polymer, and

binding the block copolymer to the microcapsule to form a non-ionic, hydrophilic outerlayer.

18. The method of claim 17, wherein the improvement in biocompatibility after treatment with the graft copolymer is detected as at least one of:

a) decrease, after treatment, of adherence to a microcapsule of cells from an animal;

b) decrease, after treatment, of the immune response of an animal to a microcapsule;

or

c) decrease, after treatment, of overgrowth of a microcapsule by cells from an animal.

19. A method for treating a surface comprising a polyanionic polymer to improve its biocompatibility and resistance to cellular overgrowth and protein adhesion comprising:

attaching to the surface a water-soluble block copolymer comprising a water-soluble non-ionic polymer grafted to a polycationic polymer, and

binding the water-soluble block copolymer to the polyanionic polymer surface to form a non-ionic, hydrophilic layer on the surface.

20. The method of claim 19, wherein the block copolymer adheres to the surface by ionic crosslinking.

21. The method of claim 19, wherein the polycationic polymer is selected from the group consisting of polypeptides, polyimines, and polyallylamines, and wherein the weight average molecular weight of the polycationic polymer is between 10,000 and 75,000 daltons.

22. The method of claim 21, wherein the polycationic polymer is selected from the group consisting of polylysine, polyornithine, polyethyleneimine, polyallylamine, mixed copolymers thereof, and mixtures thereof.

23. The method of claim 19, wherein the non-ionic water-soluble polymer is selected from the group consisting of poly(ethylene oxide), poly(vinylpyrrolidone), poly(ethyloxazoline), poly(vinyl alcohol), and polysaccharides, and wherein the weight average molecular weight of the non-ionic water-soluble polymer is between 2000 and 50,000 daltons.

24. The method of claim 19, wherein the improvement in biocompatibility after treatment with the graft copolymer is detected as at least one of:

a) decrease, after treatment, of adherence to the surface of cells from an animal;

b) decrease, after treatment, of the immune response of an animal to the surface;

or

c) decrease, after treatment, of overgrowth of the surface by cells from an animal.